121 related articles for article (PubMed ID: 35104793)
21. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
22. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.
Lau D; Hervey-Jumper SL; Chang S; Molinaro AM; McDermott MW; Phillips JJ; Berger MS
J Neurosurg; 2016 May; 124(5):1300-9. PubMed ID: 26544781
[TBL] [Abstract][Full Text] [Related]
23. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
[TBL] [Abstract][Full Text] [Related]
27. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
28. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
30. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
Mair MJ; Pajenda S; Ilhan-Mutlu A; Steindl A; Kiesel B; Widhalm G; Dieckmann K; Feldmann K; Hainfellner J; Marosi C; Müllauer L; Wagner L; Preusser M; Berghoff AS
ESMO Open; 2020 Nov; 5(6):e000863. PubMed ID: 33184096
[TBL] [Abstract][Full Text] [Related]
31. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
[TBL] [Abstract][Full Text] [Related]
32. Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.
Clavreul A; Etcheverry A; Tétaud C; Rousseau A; Avril T; Henry C; Mosser J; Menei P
J Neurooncol; 2015 Mar; 122(1):1-10. PubMed ID: 25503303
[TBL] [Abstract][Full Text] [Related]
33. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
Front Immunol; 2020; 11():588552. PubMed ID: 33329573
[TBL] [Abstract][Full Text] [Related]
34. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
[TBL] [Abstract][Full Text] [Related]
35. Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma.
Mir Seyed Nazari P; Berghoff AS; Preusser M; Moik F; Posch F; Ricken G; Riedl J; Hell L; Marosi C; Hainfellner JA; Pabinger I; Ay C
ESMO Open; 2020 May; 5(3):e000647. PubMed ID: 32424065
[TBL] [Abstract][Full Text] [Related]
36. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
Ene CI; Kreuser SA; Jung M; Zhang H; Arora S; White Moyes K; Szulzewsky F; Barber J; Cimino PJ; Wirsching HG; Patel A; Kong P; Woodiwiss TR; Durfy SJ; Houghton AM; Pierce RH; Parney IF; Crane CA; Holland EC
Neuro Oncol; 2020 May; 22(5):639-651. PubMed ID: 31793634
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
38. Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment.
Cai X; Yuan F; Zhu J; Yang J; Tang C; Cong Z; Ma C
Front Oncol; 2021; 11():672928. PubMed ID: 33996602
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
40. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
